TNFRSF4 and neoplasm: showed that the OX40 agonist SHR-1806 markedly increased IFN-γ secretion, promoted antitumor T cell responses, and preserved both antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity to eliminate Tregs and achieve tumor regression (123).